AM

Ashutosh Mishra

Director Director DIN 09096165
DIN 09096165 First appointment Mar 2021 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Mar 2021
Shareholding value β€’β€’β€’β€’ Premium profile

About Ashutosh Mishra

Data last updated:

Ashutosh Mishra was a Director at Avunu Lifesciences Private Limited (2021–2025) and Director at Sinzant Biotech Private Limited (2021). The companies operate in Pharma and Healthcare.

DIN 09096165
Primary Designation Director
Industry Pharma
First Appointment 08 Mar 2021

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Avunu Lifesciences Private Limited U85300HR2021PTC093436
Director08 Mar 20212021₹2.47 Cr (FY 2024)Active
Sinzant Biotech Private Limited U85100UR2021PTC012909
Director10 Sep 20212021Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Avunu Lifesciences Private Limited
Sinzant Biotech Private Limited
Premium access

Shareholding and investment profile for Ashutosh Mishra

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ashutosh Mishra

Ashutosh Mishra was first appointed on 08 Mar 2021 as Director at Avunu Lifesciences Private Limited.

Ashutosh Mishra held 2 earlier board appointments: Avunu Lifesciences Private Limited (Director, 08 Mar 2021 to 18 Jan 2025); Sinzant Biotech Private Limited (Director, 10 Sep 2021 to 06 Oct 2021).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available